LTBP3

Across TCGA pan-cancer cohorts, LTBP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LTBP3 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LTBP3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LTBP3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.

SKCM, BLCA, and STAD are the cancer types where LTBP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.911	0.489	.029	11	view →
BLCA	OS	Median	II,III,IV	1.000	0.414	.028	8	view →
STAD	OS	Median	II,III,IV	0.884	0.385	.025	7	view →
COAD	DFS	Median	All	0.223	0.696	.017	6	view →
UCEC	OS	Median	All	1.000	0.660	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LTBP3–SKCM (DFS)

Open the SKCM breakdown →